Abstract
S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976–1.000), 0.678 (95% CI 0.563–0.792) and 0.807 (95% CI 0.715–0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.
Similar content being viewed by others
Abbreviations
- ANA:
-
Anti-nuclear antibodies
- anti-dsDNA:
-
Anti-double-stranded DNA antibody
- BILAG:
-
British Isles Lupus Assessment Group disease activity index
- CI:
-
Confidence interval
- c-SLEDAI-2 K:
-
Systemic lupus erythematosus Disease Activity Index 2000 clinical items
- DAMPs:
-
Damage-associated molecular patterns
- ELISA:
-
Enzyme-linked immunosorbent assay
- EMT:
-
Epithelial–mesenchymal transition
- GC:
-
Glucocorticoids
- HCs:
-
Healthy controls
- IF:
-
Immunofluorescence
- IS:
-
Immunosuppressants
- LIA:
-
Line immunoassay
- ROC:
-
Receiver operating characteristic
- SD:
-
Standard deviation
- SLE:
-
Systemic lupus erythematosus
- SLEDAI-2K:
-
Systemic Lupus Erythematosus Disease Activity Index 2000
- SLICC/ACR:
-
Systemic Lupus International Collaborating Clinics/American College of Rheumatology
- RA:
-
Rheumatoid arthritis
- RAGE:
-
The receptor for advanced glycation end product
References
Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384:1878–1888. https://doi.org/10.1016/S0140-6736(14)60128-8
Ahearn JM, Liu C-C, Kao AH, Manzi S (2012) Biomarkers for systemic lupus erythematosus. Transl Res 159:326–342. https://doi.org/10.1016/j.trsl.2012.01.021
Tektonidou MG, Ward MM (2011) Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol 7:708–717. https://doi.org/10.1038/nrrheum.2011.157
Aletaha D, Smolen J The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100-8
Herbst R, Liu Z, Jallal B, Yao Y (2012) Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 15:433–444. https://doi.org/10.1111/j.1756-185X.2012.01764.x
Sedaghat F, Notopoulos A (2008) S100 protein family and its application in clinical practice. Hippokratia 12:198–204. https://doi.org/10.1016/j.amjsurg.2009.11.010
Bresnick AR, Weber DJ, Zimmer DB (2015) S100 proteins in cancer. Nat Rev Cancer 15:96–109. https://doi.org/10.1038/nrc3893
Chen H (2014) S100 protein family in human cancer. Am J Cancer Res 4:89–115. https://doi.org/10.1053/j.jvca.2004.07.027
Nordal H, Brun J, Hordvik M et al (2016) Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Scand J Rheumatol 45:274–281. https://doi.org/10.3109/03009742.2015.1107128
Andrés Cerezo L, Mann H, Pecha O et al (2011) Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 13:R122. https://doi.org/10.1186/ar3426
Klingelhöfer J, Šenolt L, Baslund B et al (2007) Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: Putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheumatol 56:779–789. https://doi.org/10.1002/ART.22398
Šenolt L, Andres Cerezo L, Šumová B et al (2015) High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers 20:47–51. https://doi.org/10.3109/1354750X.2014.989544
Pleštilová L, Mann H, Andrés Cerezo L et al (2014) The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Res Ther 16:468. https://doi.org/10.1186/s13075-014-0468-2
Foell D, Roth J (2004) Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50:3762–3771. https://doi.org/10.1002/art.20631
Foell D, Wittkowski H, Vogl T, Roth J (2006) S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81:28–37. https://doi.org/10.1189/jlb.0306170
Bian L, Strzyz P, Jonsson IM et al (2011) S100a4 deficiency is associated with efficient bacterial clearance and protects against joint destruction during staphylococcal infection. J Infect Dis 204:722–730. https://doi.org/10.1093/infdis/jir369
Donato R, Cannon BR, Sorci G et al (2013) Functions of S100 proteins. Curr Mol Med 13:24–57. https://doi.org/10.2174/1566524011307010024
Andrés Cerezo L, Remá ková M, Tomčik M et al (2014) The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatol (United Kingdom) 53:1520–1526. https://doi.org/10.1093/rheumatology/keu031
Tomcik M, Palumbo-Zerr K, Zerr P et al (2014) S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2013-204516
Schneider M, Hansen JL, Sheikh SP (2008) S100A4: a common mediator of epithelial–mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med 86:507–522. https://doi.org/10.1007/s00109-007-0301-3
Soyfoo MS, Roth J, Vogl T et al (2009) Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 36:2190–2194. https://doi.org/10.3899/jrheum.01302
Tyden H, Lood C, Gullstrand B et al (2013) Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology 52:2048–2055. https://doi.org/10.1093/rheumatology/ket263
Turnier JL, Fall N, Thornton S et al (2017) Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Res Ther 19:242. https://doi.org/10.1186/s13075-017-1444-4
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/1529-0131(199709)40:9%3C1725::AID-ART29%3E3.0.CO;2-Y
Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291
Abrahamowicz M, Fortin PR, Du Berger R et al (1998) The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 25:277–284
Zibert JR, Skov L, Thyssen JP et al (2009) Significance of the S100A4 protein in psoriasis. J Invest Dermatol 130:150–160. https://doi.org/10.1038/jid.2009.206
Fei F, Qu J, Zhang M et al (2017) S100A4 in cancer progression and metastasis: a systematic review. Oncotarget 8:73219–73239. https://doi.org/10.18632/oncotarget.18016
Lozano S, Mossad E (2004) Cerebral function monitors during pediatric cardiac surgery: can they make a difference? J Cardiothorac Vasc Anesth 18:645–656. https://doi.org/10.1053/j.jvca.2004.07.027
Grigorian MS, Tulchinsky EM, Zain S et al (1993) The mts1 gene and control of tumor metastasis. Gene 135:229–238. https://doi.org/10.1016/0378-1119(93)90070-J
Okada H, Danoff TM, Kalluri R, Neilson EG (1997) Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273:F563–F574
Grigorian M, Andresen S, Tulchinsky E et al (2001) Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 276:22699–22708. https://doi.org/10.1074/jbc.M010231200
Orre LM, Panizza E, Kaminskyy VO et al (2013) S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene 32:5531–5540. https://doi.org/10.1038/onc.2013.213
Li ZH, Bresnick AR (2006) The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res doi. https://doi.org/10.1158/0008-5472.CAN-05-3087
Xu H, Li M, Zhou Y et al (2016) S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2. Tumor Biol 37:2925–2932. https://doi.org/10.1007/s13277-015-3709-3
Davies BR, O’Donnell M, Durkan GC et al (2002) Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 196:292–299. https://doi.org/10.1002/path.1051
Hemandas AK, Salto-Tellez M, Maricar SH et al (2006) Metastasis-associated protein S100A4—a potential prognostic marker for colorectal cancer. J Surg Oncol 93:498–503. https://doi.org/10.1002/jso.20460
Chow K-H, Park HJ, George J et al (2017) S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res 77:5360–5373. https://doi.org/10.1158/0008-5472.CAN-17-1294
Haga HJ, Brun JG, Berntzen HB et al (1993) Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 2:47–50. https://doi.org/10.1177/096120339300200108
Lood C, Tydén H, Gullstrand B et al (2016) Platelet-derived S100A8/A9 and cardiovascular disease in systemic lupus erythematosus. Arthritis Rheumatol 68:1970–1980. https://doi.org/10.1002/art.39656
Tantivitayakul P, Benjachat T, Somparn P et al (2016) Elevated expressions of myeloid-related proteins-8 and -14 are danger biomarkers for lupus nephritis. Lupus 25:38–45. https://doi.org/10.1177/0961203315598015
Hakkim A, Fürnrohr BG, Amann K et al (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107:9813–9818. https://doi.org/10.1073/pnas.0909927107
Ren Y, Tang J, Mok MY et al (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888–2897. https://doi.org/10.1002/art.11237
Muñoz LE, Janko C, Franz S et al (2012) Immune complex formation after exposure of autoantigens on the surface of secondary necrotic cells (SNEC) promotes inflammation in SLE. Ann Rheum Dis 71:A73.1–A73. https://doi.org/10.1136/annrheumdis-2011-201238.2
Donnelly S, Roake W, Brown S et al (2006) Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum 54:1543–1556. https://doi.org/10.1002/art.21783
Cappione A, Anolik JH, Pugh-Bernard A et al (2005) Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115:3205–3216. https://doi.org/10.1172/JCI24179
Kalaaji M, Mortensen E, Jørgensen L et al (2006) Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 168:1779–1792. https://doi.org/10.2353/ajpath.2006.051329
Uccellini MB, Avalos AM, Marshak-Rothstein A, Viglianti GA (2009) Toll-like receptor-dependent immune complex activation of B cells and dendritic cells. Humana Press, Totowa, pp 363–380
Lood C, Stenström M, Tydén H et al (2011) Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther 13:R60. https://doi.org/10.1186/ar3314
Ghosh HS, Cisse B, Bunin A et al (2010) Continuous expression of the transcription factor E2-2 maintains the cell fate of mature plasmacytoid dendritic cells. Immunity 33:905–916. https://doi.org/10.1016/j.immuni.2010.11.023
Bianchi ME (2006) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5. https://doi.org/10.1189/jlb.0306164
Ghavami S, Eshragi M, Ande SR et al (2010) S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res 20:314–331. https://doi.org/10.1038/cr.2009.129
Gestermann N, Di Domizio J, Lande R et al (2018) Netting neutrophils activate autoreactive B cells in lupus. J Immunol 200:3364–3371. https://doi.org/10.4049/jimmunol.1700778
Villanueva E, Yalavarthi S, Berthier CC et al (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187:538–552. https://doi.org/10.4049/jimmunol.1100450
Brinkmann V, Reichard U, Goosmann C et al (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532–1535. https://doi.org/10.1126/science.1092385
Lande R, Ganguly D, Facchinetti V et al (2012) Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci Transl Med 3:1–20. https://doi.org/10.1126/scitranslmed.3001180.Neutrophils
Garcia-Romo GS, Caielli S, Vega B et al (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3:73ra20. https://doi.org/10.1126/scitranslmed.3001201
Hakkim A, Furnrohr BG, Amann K et al (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci 107:9813–9818. https://doi.org/10.1073/pnas.0909927107
Urban CF, Ermert D, Schmid M et al (2009) Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 5:e1000639. https://doi.org/10.1371/journal.ppat.1000639
Richardson BC, Yung RL, Johnson KJ et al (1996) Monocyte apoptosis in patients with active lupus. Arthritis Rheum 39:1432–1434
Acknowledgements
We would like to thank Milada Lösterová for the excellent work as a study nurse in the management of the study.
Funding
This study was supported by the project of the Ministry of Health of the Czech Republic for conceptual development of research organization [Grant no. 00023728].
Author information
Authors and Affiliations
Contributions
Substantial contributions to the conception or design of the work: BS, MG, JZ, LS, LAC, KP, JV. Substantial contributions to the acquisition, analysis, or interpretation of data for the work: BS, HH, JZ, LS, LSz, LN, MU, LAC, JV. Drafting the work or revising it critically for important intellectual content: BS, HH, MG, LS, JZ, LSz, LN, MU, LAC, KP, JV. Final approval of the version to be published: BS, HH, MG, JZ, LS, LSz, LN, MU, LAC, KP, JV. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: BS, HH, MG, JZ, LS, LSz, LN, MU, LAC, KP, JV.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and bits later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Šumová, B., Cerezo, L.A., Szczuková, L. et al. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatol Int 39, 469–478 (2019). https://doi.org/10.1007/s00296-018-4190-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-018-4190-2